Tetra Bio-Pharma is a Canadian company that specializes in investigating the use of plant based and synthetic cannabinoids for treating a variety of diseases.
One molecule of interest that they have worked with is HU-308, a synthetic cannabinoid that acts as a selective CB2 mimic or agonist. The company announced that they obtained approval from the US FDA to conduct phase I clinical trials to determine if HU-308 is useful for treating Covid-19 Acute Respiratory Distress Syndrome (ARDS). If Phase I trials are successfully concluded and followed by positive Phase II testing, HU-308 ~might~ be approved in late 2021 (though the process is highly speculative).
HU-308 was developed in the lab of Raphael Mechoulam; he was the scientist who discovered that THC was the psychoactive component in marijuana, and he played key roles in the discovery of the CB receptors and in many studies investigating the medical uses of cannabis.